Changes in serum anti-mullerian hormone level during low-dose recombinant follicular-stimulating hormone therapy for anovulation in polycystic ovary syndrome

被引:62
作者
Catteau-Jonard, Sophie
Pigny, Pascal
Reyss, Anne-Celine
Decanter, Christine
Poncelet, Edouard
Dewailly, Didier
机构
[1] Ctr Hosp Reg Univ Lille, Hop Jeanne Flandre, Dept Endocrine Gynaecol & Reprod Med, F-59037 Lille, France
[2] Ctr Hosp Reg Univ Lille, Hop Jeanne Flandre, Dept Radiol, F-59037 Lille, France
[3] Ctr Hosp Reg Univ Lille, Lab Endocrinol, F-59037 Lille, France
关键词
D O I
10.1210/jc.2007-0868
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context: We previously hypothesized that the excess of anti-mullerian hormone (AMH) at the level of selectable follicles could be involved in the follicular arrest of polycystic ovary syndrome ( PCOS), mainly through inhibition of FSH effect on aromatase expression. Objective: In this study, we investigated whether a decrease in the serum AMH level was concomitant to the appearance of a dominant follicle induced by administration of mild amounts of exogenous FSH in women with PCOS. Design: A total of 30 women with PCOS in whom anovulation was resistant to clomiphene citrate received recombinant FSH using the low-dose step-up protocol during only one cycle. Serum levels of estradiol, AMH, LH, FSH, inhibin B, and ultrasound parameters were assessed twice a week until 3 d after the appearance of one or more dominant follicle(s). Results: The day of dominance ( d 0) was defined by the appearance of at least one follicle more than 10 mm growing 2 mm/d. From d - 14 before dominance to d - 3, the mean serum AMH level and the 2- to 5-mm follicle number at ultrasound declined steadily, although not significantly by ANOVA. Mean AMH relative values (100% being the value at d 0) declined significantly ( P = 0.04), from 125 +/- 32% at d - 14 to 105 +/- 15% at d - 4. Within the same time lag, the mean FSH relative values increased from 91 +/- 17% to 107 +/- 19% ( P = 0.013). In the 87 samples obtained from d - 14 to -4, absolute values of AMH were positively and negatively associated with those of LH and FSH, respectively, in an independent manner ( P = 0.009 and P = 0.03, respectively). In the 55 samples collected at d 0 and +3, they were negatively correlated to those of estradiol ( r = -0.272; P < 0.05). Conclusions: These data suggest that in anovulatory women with PCOS, gently increasing the serum FSH level reduces the AMH excess, thus relieving the inhibition from the latter on aromatase expression by selectable follicles and allowing the emergence of a dominant follicle.
引用
收藏
页码:4138 / 4143
页数:6
相关论文
共 31 条
[11]   Serum anti-Mullerian hormone levels during controlled ovarian hyperstimulation in women with polycystic ovaries with and without hyperandrogenism [J].
Eldar-Geva, T ;
Margalioth, EJ ;
Gal, M ;
Ben-Chetrit, A ;
Algur, N ;
Zylber-Haran, E ;
Brooks, B ;
Huerta, M ;
Spitz, IM .
HUMAN REPRODUCTION, 2005, 20 (07) :1814-1819
[12]   Serum anti-Mullerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3 [J].
Fanchin, R ;
Schonäuer, LM ;
Righini, C ;
Guibourdenche, J ;
Frydman, R ;
Taieb, J .
HUMAN REPRODUCTION, 2003, 18 (02) :323-327
[13]   Serum anti-Mullerian hormone dynamics during controlled ovarian hyperstimulation [J].
Fanchin, R ;
Schonäuer, LM ;
Righini, C ;
Frydman, N ;
Frydman, R ;
Taieb, J .
HUMAN REPRODUCTION, 2003, 18 (02) :328-332
[14]   Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS) [J].
Fauser, BCJM ;
Chang, J ;
Azziz, R ;
Legro, R ;
Dewailly, D ;
Franks, S ;
Tarlatzis, BC ;
Fauser, B ;
Balen, A ;
Bouchard, P ;
Dahlgren, E ;
Devoto, L ;
Diamanti, E ;
Dunaif, A ;
Filicori, M ;
Homburg, R ;
Ibanez, L ;
Laven, J ;
Magoffin, D ;
Nestler, J ;
Norman, RJ ;
Pasquali, R ;
Pugeat, M ;
Strauss, J ;
Tan, S ;
Taylor, A ;
Wild, R ;
Wild, S ;
Ehrmann, D ;
Lobo, R .
HUMAN REPRODUCTION, 2004, 19 (01) :41-47
[15]   Manipulation of human ovarian function: Physiological concepts and clinical consequences [J].
Fauser, BCJM ;
VanHeusden, AM .
ENDOCRINE REVIEWS, 1997, 18 (01) :71-106
[16]   MEDICAL PROGRESS - POLYCYSTIC-OVARY-SYNDROME [J].
FRANKS, S .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (13) :853-861
[17]   Regulation of ovarian follicular development in primates: Facts and hypotheses [J].
Gougeon, A .
ENDOCRINE REVIEWS, 1996, 17 (02) :121-155
[18]   LOW-DOSE GONADOTROPIN THERAPY FOR INDUCTION OF OVULATION IN 100 WOMEN WITH POLYCYSTIC-OVARY-SYNDROME [J].
HAMILTONFAIRLEY, D ;
KIDDY, D ;
WATSON, H ;
SAGLE, M ;
FRANKS, S .
HUMAN REPRODUCTION, 1991, 6 (08) :1095-1099
[19]   Anti-Mullerian hormone levels in the spontaneous menstrual cycle do not show substantial fluctuation [J].
Hehenkamp, Wouter J. K. ;
Looman, Caspar W. N. ;
Themmen, Axel P. N. ;
de Jong, Frank H. ;
te Velde, E. R. ;
Broekmans, Frank J. M. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (10) :4057-4063
[20]  
JAKIMIUK AJ, 1997, ASSIS REPROD REV, V7, P54